Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
Global Leaders Driving The Future Of Healthcare At The 2025 Forbes Healthcare Summit [Forbes]
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile [Yaho